April.2017-March.2018

Announcement of the progress of Phase III clinical study of the cancer-specific peptide vaccine S-588410

Announcement of research collaboration between OTS’s subsidiary company and Japanese Foundation for Cancer Research (JFCR)

Announcement of partnership between OTS’s subsidiary company and Thermo Fisher Scientific to evaluate new liquid biopsy platform

Announcement of research collaboration between OTS’s subsidiary company and Itabashi Medical System (IMS) group

The announcement of the initiation of a Phase I/II clinical study for OTS167 in patients with refractory or relapsed leukemia at Weill Cornell Medicine

The first-patient enrollment in Phase I clinical study of OTS167, MELK specific inhibitor, for breast cancer patients

Patent Registration for MELK-specific inhibitors in European Patent Office

Announcement of collaboration with three medical corporations for development of dendritic cell-based cancer immunotherapy

Patent Registration for MELK-specific inhibitors in Japan

Announcement of establishment of a new subsidiary company in collaboration with Theragen Etex Co., Ltd.

Announcement of milestone payment for the progress of Phase III clinical trial of the cancer-specific peptide vaccine S-588410

Phase I clinical study for OTS167 in patients with breast cancer, including triple-negative breast cancer, opens

The announcement of initiation of Phase I clinical study for OTS167 (oral administration) in patients with Breast Cancer including Triple-Negative Breast Cancer at Weill Cornell Medicine